TTF1 and lung adenocarcinoma: TTF-1 amplification, on the other hand, has been detected in both lung adenocarcinomas (18.9%) and squamous cell carcinomas (20.1%) and correlated significantly with the presence of KRAS mutations in the adenocarcinoma subset [8-10, 17].